Advances in myelofibrosis: A clinical case approach

Haematologica

Volumn 98, Issue 10, 2013, Pages 1499-1509

  Mascarenhas, John O ^a   Orazi, Attilio ^b   Bhalla, Kapil N ^c   Champlin, Richard E ^d   Harrison, Claire ^e   Hoffman, Ronald ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL) IMIDAZO [4, 5 C] QUINOLIN 2 (1H, 3H) ONE; 1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 5 AZA 2' DEOXYCYTIDINE; ACETYLSALICYLIC ACID; AZACITIDINE; BC 2059; BUSULFAN; CLADRIBINE; CORTICOSTEROID; DANAZOL; DNA METHYLTRANSFERASE INHIBITOR; FEDRATINIB; FLUDARABINE; GIVINOSTAT; HYDROXYUREA; INTERFERON; JANUS KINASE 2; LACTATE DEHYDROGENASE; LOW MOLECULAR WEIGHT HEPARIN; LUMINESPIB; METOPROLOL; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL) PHENYLAMINO] 4 PYRIMIDINYLAMINO] BENZENESULFONAMIDE; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PACRITINIB; PANOBINOSTAT; PEGINTERFERON; PLACEBO; PRACINOSTAT; PREDNISONE; PU H71; RUXOLITINIB; SELUMETINIB; SGI 1776; UNCLASSIFIED DRUG;

ANEMIA; ANOREXIA; APOPTOSIS; BLEEDING DISORDER; CELL DIFFERENTIATION; DIARRHEA; DIZZINESS; DNA METHYLATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; EPIGENETICS; EXTRAMEDULLARY HEMATOPOIESIS; FATIGUE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GRANULOPOIESIS; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HYPERURICEMIA; LOW DRUG DOSE; MEGAKARYOPOIESIS; MULTICENTER STUDY (TOPIC); MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NAUSEA; NEUTROPENIA; NIGHT SWEAT; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYCYTHEMIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOSIS; ULCER;

ADULT; AGED; ANIMALS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES;

EID: 84884970610     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.086348     Document Type: Review

References (62)

1. Thiele J, Kvasnicka HM, Tefferi A, et al. Primary myelofibrosis. In: Swerdlow SH, Campo E, Harris NL et al, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Lyon: World Health Organization, 2008:44-7.
2. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-901.
3. Cervantes F, Dupriez B, Passamonti F, Vannucchi AM, Morra E, Reilly JT, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol. 2012;30(24):2981-7.
4. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWGMRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-8.
5. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-70.
6. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7(9):673-83.
7. Zhan H, Spivak JL. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. Clin Adv Hematol Oncol. 2009;7(5):334-42.
8. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005; 106(6):2162-8.
9. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14-22.
10. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHOdefined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia. 2013. [Epub ahead of print]
11. Thiele J, Kvasnicka HM, Mullauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood. 2011;117(21):5710-8.
12. Barbui T, Thiele J, Carobbio A, Passamonti F, Rumi E, Randi ML, et al. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood. 2012;120(3):569-71.
13. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179-84.
14. Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012;26 (4):716-9.
15. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-7.
16. Incyte Corporation. Jakafi (R) (ruxolitinib) Full prescribing information. Available from: http://www.incyte.com/products/uspi_jaka fi.pdf. Accessed 20 February 2013.
17. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12): 1117-27.
18. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
19. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-98.
20. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: Durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I. Blood. 2012;120(21):Abstract 800.
21. Cervantes F, Kiladjian JJ, Niederwieser D, Sirulnik A, Stalbovskaya V, McQuity M, et al. Long-term safety, efficacy, and survival findings from Comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood. 2012;120:(Abstract 801).
22. Harrison CN, Kiladjian JJ, Gisslinger H, Niederwieser D, Passamonti F, Waltzman RJ, et al. Ruxolitinib provides reductions in splenomegaly across subgroups; An analysis of spleen response in the COMFORT-II study. Blood. 2011;118:Abstract 279.
23. Talpaz M, Hamburg SI, Jamieson K, Terebelo HR, Afrin L, Winton EF, et al. Preliminary safety and eficiacy from a phase II study of ruxolitinib in patients with primary and secondary myelofibrosis with platelets counts of 50-100 x 109/L. Haematologica. 2012;97:244 Abstract 597.
24. Harrison CN, Gisslinger H, Miller CB, Kiladjian JJ, Atienza E, Stalbovskaya V, et al. Expand: a phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 5x109/L and 99x109/L. Blood. 2012;120 (21):Abstract 177.
25. Tefferi A, Litzow MR, Pardanani A. Longterm outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011;365(15):1455-7.
26. Pardanani A, Gotlib J, Jamieson C, Cortes JE, Talpaz M, Stone R, et al. SAR302503: Interim safety, efficacy and long-term impact on JAK2 V617F allele burden in a phase I/II study in patients with myelofibrosis. Blood. 2011;118(21):Abstract 3838.
27. Talpaz M, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, et al. A phase II randomized dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), or post-essential thrombocythemia (ET) MF. Blood. 2012;120(21):Abstract 2837.
28. Komrokji RS, Wadleigh M, Seymour JF, Roberts AW, To LB, Zhu HJ, et al. Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and postessential thrombocythemia myelofibrosis. Blood. 2011;118(21):Abstract 282.
29. Pardanani A, Gotlib J, Gupta V, Roberts AW, Wadleigh M, Sirhan S, et al. Phase I/II study of CYT387, a JAK1/JAK2 inhibitor for the treatment of myelofibrosis. Blood. 2012;120(21):Abstract 178.
30. Wang JC, Chen W, Nallusamy S, Chen C, Novetsky AD. Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. Br J Haematol. 2002;116(3):582-6.
31. Jones LC, Tefferi A, Idos GE, Kumagai T, Hofmann WK, Koeffler HP. RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia. Oncogene. 2004;23(47):7846-53.
32. Bogani C, Ponziani V, Guglielmelli P, Desterke C, Rosti V, Bosi A, et al. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells. 2008;26(8):1920-30.
33. Teofili L, Martini M, Cenci T, Guidi F, Torti L, Giona F, et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer. 2008;123(7):1586-92.
34. Mascarenhas J, Roper N, Chaurasia P, Hoffman R. Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clin Epigenetics. 2011;2(2):197-212.
35. Wang JC, Chen C, Dumlao T, Naik S, Chang T, Xiao YY, et al. Enhanced histone deacetylase enzyme activity in primary myelofibrosis. Leuk Lymphoma. 2008;49(12):2321-7.
36. Shi J, Zhao Y, Ishii T, Hu W, Sozer S, Zhang W, et al. Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res. 2007;67(13):6417-24.
37. Wang X, Zhang W, Ishii T, Sozer S, Wang J, Xu M, et al. Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents. Cancer Res. 2009;69(19):7612-8.
38. Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, Carobbio A, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia. 2008;22(4):740-7.
39. Garcia-Manero G, Chuah C, Wilding G, Chang J, Verstovsek S, Faderl S, et al. Phase I study of the oral histone deacetylase inhibitor SB939 in patients with advanced hematologic malignancies. Blood. 2010;116: Abstract 3292.
40. Wang H, Yu N, Chen D, Lee KC, Lye PL, Chang JW, et al. Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylami de (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile. J Med Chem. 2011;54(13):4694-720.
41. Quintas-Cardama A, Kantarjian H, Estrov Z, Borthakur G, Cortes J, Verstovsek S. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 2012;36(9):1124-7.
42. Golay J, Cuppini L, Leoni F, Mico C, Barbui V, Domenghini M, et al. The histone deacetylase inhibitor ITF2357 has antileukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia. 2007;21(9):1892-900.
43. Rambaldi A, Dellacasa CM, Finazzi G, Carobbio A, Ferrari ML, Guglielmelli P, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150(4): 446-55.
44. Rambaldi A, Finazzi G, Vannucchi AM, Martinelli V, Rodeghiero F, Nobile F, et al. A phase II study of the HDAC inhibitor givinostat in combination with hydroxyurea in patients with polycythemia vera resistant to hydroxyurea monotherapy. Blood. 2011; 118:Abstract 1748.
45. Prince HM, George D, Patnaik A, Mita M, Dugan M, Butterfoss D, et al. Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and nonhodgkin's lymphoma. J Clin Oncol. 2007; 25(18S):Abstract 3500.
46. Spencer A, Prince M, De Angelo DJ, Fischer T, Bhalla KN, Giles FJ, et al. Phase IA/II study of oral LBH589, a novel deacetylase inhibitor (DACi), administered on 2 schedules, in patients with advanced hematologic malignancies. Blood. 2007;110: Abstract 907.
47. Sharma S, Vogelzang NJ, Beck J, Patnaik A, Mita M, Dugan M, et al. Phase I pharmacokinetic and pharmacodynamic study of once-weekly IV LBH589. Eur J Cancer. 2007;5(4):107: Abstract 702.
48. DeAngelo DJ, Tefferi A, Fiskus W, Mesa RA, Paley CS, Wadleigh M, et al. A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), post essential thrombocythemia (ET), and post polycythemia vera (PV) myelofibrosis. Blood. 2010;116:Abstract 630.
49. Mascarenhas J, Lu M, Li T, Petersen B, Hochman T, Najfeld V, et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Br J Haematol. 2013;161(1):68-75.
50. Baffert F, Evrot E, Ebel N, Roelli C, Andraos R, Qian Z, et al. Improved efficacy upon combined JAK1/2 and pan-deacetylase inhibition using ruxolitinib (INC424) and panobinostat (LBH589) in preclinical mouse models of JAK2V617-F-driven disease. Blood. 2011;118: Abstract 798.
51. Fiskus W, Ganguly S, Kambhampati S, Bhalla KN. Role of additional novel therapies in myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2012;26(5):959-80.
52. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5(10):761-72.
53. Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, Rao R, et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood. 2009;114(24): 5024-33.
54. Fiskus W, Verstovsek S, Manshouri T, Rao R, Balusu R, Venkannagari S, et al. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. Clin Cancer Res. 2011;17(23):7347-58.
55. Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012;489(7414):155-9.
56. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4(5):335-48.
57. Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood. 2011;118(8):2069-76.
58. Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, Bosi A, et al. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. PLoS One. 2013;8(1):e54826.
59. Fiskus W, Verstovsek S, Manshouri T, Smith JE, Peth K, Abhyankar S, et al. Mol Cancer Ther. 2013;12(5):577-88.
60. Scott BL, Gooley TA, Sorror ML, Rezvani AR, Linenberger ML, Grim J, et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood. 2012;119(11):2657-64.
61. Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114 (26):5264-70.
62. Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood. 2012;120(7):1367-79.